NCT06617793 - An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 24, 2025

Primary Completion Date

October 1, 2030

Study Completion Date

October 1, 2030

Conditions

Relapsing Multiple Sclerosis

Interventions

BIOLOGICAL

rapcabtagene autoleucel (YTB323)

CAR-T cell suspension for intravenous infusion

Trial Locations (16)

1011

RECRUITING

Novartis Investigative Site, Lausanne

2010

RECRUITING

Novartis Investigative Site, Darlinghurst

3004

RECRUITING

Novartis Investigative Site, Melbourne

3010

RECRUITING

Novartis Investigative Site, Bern

8091

RECRUITING

Novartis Investigative Site, Zurich

14004

RECRUITING

Novartis Investigative Site, Córdoba

16132

RECRUITING

Novartis Investigative Site, Genova

20132

RECRUITING

Novartis Investigative Site, Milan

34090

RECRUITING

Novartis Investigative Site, Montpellier

35000

RECRUITING

Novartis Investigative Site, Rennes

44791

RECRUITING

Novartis Investigative Site, Bochum

45147

RECRUITING

Novartis Investigative Site, Essen

46026

RECRUITING

Novartis Investigative Site, Valencia

54035

RECRUITING

Novartis Investigative Site, Nancy

89081

RECRUITING

Novartis Investigative Site, Ulm

08035

RECRUITING

Novartis Investigative Site, Barcelona